APOLLO Oncology Clinical Trials Program
The APOLLO Oncology Clinical Trials Program is a series of trials evaluating and investigating whether Apollomics’ c-Met inhibitor can work in concert with other agents to improve on single agent outcomes. Multiple combination trials are being initiated and/or planned with our c-Met inhibitor.
APOLLO Trial
APOLLO is a Phase 1/2, open label, two-arm, multi-center dose escalation and expansion study targeting locally advanced or metastatic disease.
clinicaltrials.gov: NCT03655613
Agents: APL-101 (c-Met inhibitor) + APL-501 (anti-PD-1)
Indication: Hepatocellular Carcinoma
Agents: APL-101 (c-Met inhibitor) + nivolumab (anti-PD-1)
Indication: Renal Cell Carcinoma
APOLLO-2 Trial
APOLLO-2 is a planned clinical trial combining APL-101 plus an approved immunotherapy with or without chemotherapy.
Agents: APL-101 (c-Met inhibitor) + I/O +/- Chemotherapy
Indication: NSCLC
